Citius Oncology Reports Positive Phase 1 LYMPHIR Data in High-Risk DLBCL, Demonstrating High Response Rates
Summary
Citius Oncology, a subsidiary of Citius Pharmaceuticals, reported positive Phase 1 clinical trial results for LYMPHIR in high-risk DLBCL, showing strong efficacy and a favorable safety profile.
Key Events
-
Positive Phase 1 Trial Results
Citius Oncology announced positive topline safety and efficacy results from an investigator-initiated Phase 1 trial of LYMPHIR™ (E7777) in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
-
High Efficacy Rates Observed
The trial demonstrated an 86% overall response rate (ORR) at one month, including 57% complete responses (CR) and 29% partial responses (PR). One-year progression-free survival was 77% and overall survival was 84%.
-
Favorable Safety Profile
LYMPHIR was well-tolerated with no dose-limiting toxicities observed, and no Grade ≥3 LYMPHIR-related immune adverse events or infusion reactions were reported.
-
Potential for Expanded Indication
These results support exploring LYMPHIR's use as an immunomodulatory strategy to enhance CAR-T therapy in DLBCL, potentially expanding its market beyond its current FDA-approved indication for CTCL.
Analysis
Citius Pharmaceuticals' majority-owned subsidiary, Citius Oncology, announced positive topline Phase 1 results for LYMPHIR™ (E7777) in high-risk relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This is a significant development as it suggests potential for LYMPHIR beyond its current FDA-approved indication for CTCL. The high overall response rate (86%) and complete response rate (57%) in a challenging patient population, coupled with a favorable safety profile, provide an encouraging signal for further development. For a company facing a going concern warning and Nasdaq non-compliance, positive clinical data like this is crucial for demonstrating pipeline value and potentially attracting future investment or partnerships, which could alleviate financial pressures.
At the time of this filing, CTXR was trading at $0.77 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.6M. The 52-week trading range was $0.63 to $2.48. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.